Hypertension in kidney transplantation: a consensus statement of the 'hypertension and the kidney' working group of the European Society of Hypertension

Autor: Alexandre Persu, Davide Bolignano, Michel Burnier, Charles J. Ferro, Gérard M. London, Jean-Michel Halimi, Pantelis Sarafidis, Anna Pisano, Alberto Ortiz, Francesca Mallamaci, Nada Kanaan, John Boletis, Patrick Rossignol, Liffert Vogt, Bénédicte Sautenet, Carmine Zoccali, Grégoire Wuerzner
Přispěvatelé: Service de néphrologie et immunologie clinique [CHRU Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau-Université de Tours (UT), Cardiovascular and Renal Clinical Trialists [Vandoeuvre-les-Nancy] (INI-CRCT), Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu [Nancy], French-Clinical Research Infrastructure Network - F-CRIN [Paris] (Cardiovascular & Renal Clinical Trialists - CRCT ), Universidad Autónoma de Madrid (UAM), Aristotle University of Thessaloniki, Department of Nephrology, Hippokration Hospital, Azienda Ospedaliera Ospedali Civili Riuniti, Lausanne University Hospital, Institute of Clinical Physiology, CNR, Centre Hospitalier Manhès [Fleury-Mérogis], Université Catholique de Louvain = Catholic University of Louvain (UCL), Cliniques Universitaires Saint-Luc [Bruxelles], Défaillance Cardiovasculaire Aiguë et Chronique (DCAC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Centre d'investigation clinique plurithématique Pierre Drouin [Nancy] (CIC-P), Centre d'investigation clinique [Nancy] (CIC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Hôpital Bretonneau, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), MethodS in Patients-centered outcomes and HEalth ResEarch (SPHERE), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Nantes Université - UFR des Sciences Pharmaceutiques et Biologiques (Nantes Université - UFR Pharmacie), Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ)-Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ), University Hospitals Birmingham [Birmingham, Royaume-Uni], Laiko General Hospital, University of Athens School of Medicine, National and Kapodistrian University of Athens (NKUA), Amsterdam UMC - Amsterdam University Medical Center, Università degli Studi 'Magna Graecia' di Catanzaro = University of Catanzaro (UMG), Centre Hospitalier Universitaire Vaudois [Lausanne] (CHUV), AO research is supported by FIS/Fondos FEDER (PI17/00257, PI18/01386, PI19/00588, PI19/00815, DTS18/00032, ERA-PerMed-JTC2018 (KIDNEY ATTACK AC18/00064 and PERSTIGAN AC18/00071, ISCIII-RETIC REDinREN RD016/0009), Sociedad Española de Nefrología, FRIAT, Comunidad de Madrid en Biomedicina B2017/BMD-3686 CIFRA2-CM. LV is supported by Senior Kolff grant (18OKG12) of the Dutch Kidney Foundation.This work was planned as part of the activities of the « Kidney and Hypertension » working group of the European Society of Hypertension (ESH)., European Project: PI17/00257, European Project, BOZEC, Erwan, FEDER PI17/00257 - PI17/00257 - INCOMING, ISCIII-RETIC REDinREN RD016/0009 - INCOMING, FEDER PI18/01386 - INCOMING, FEDER PI19/00588 - INCOMING, FEDER PI19/00815 - INCOMING, FEDER DTS18/00032 - INCOMING, KIDNEY ATTACK AC18/00064 - INCOMING, PERSTIGAN AC18/00071 - INCOMING, Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Nantes Université - UFR des Sciences Pharmaceutiques et Biologiques (Nantes Univ - UFR Pharmacie), UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - SSS/IREC/NEFR - Pôle de Néphrologie, UCL - (SLuc) Service de pathologie cardiovasculaire, UCL - (SLuc) Service de néphrologie, Nephrology, ACS - Microcirculation, APH - Health Behaviors & Chronic Diseases
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Zdroj: Journal of Hypertension
Journal of Hypertension, 2021, 39 (8), pp.1513-1521. ⟨10.1097/HJH.0000000000002879⟩
Journal of hypertension, Vol. 39, no.8, p. 1513-1521 (2021)
Journal of hypertension, 39(8), 1513-1521. Lippincott Williams and Wilkins
ISSN: 0263-6352
1473-5598
DOI: 10.1097/hjh.0000000000002879
Popis: International audience; Hypertension is common in kidney transplantation recipients and may be difficult to treat. Factors present before kidney transplantation, related to the transplantation procedure itself and factors developing after transplantation may contribute to blood pressure (BP) elevation in kidney transplant recipients. The present consensus is based on the results of three recent systematic reviews, the latest guidelines and the current literature. The current transplant guidelines, which recommend only office BP assessments for risk stratification in kidney transplant patients should be reconsidered, given the presence of white-coat hypertension and masked hypertension in this population and the better prediction of adverse outcomes by 24-h ambulatory BP monitoring as indicated in recent systematic reviews. Hypertension is associated with adverse kidney and cardiovascular outcomes and decreased survival in kidney transplant recipients. Current evidence suggests calcium channel blockers could be the preferred first-step antihypertensive agents in kidney transplant patients, as they improve graft function and reduce graft loss, whereas no clear benefit is documented for renin-angiotensin system inhibitor use over conventional treatment in the current literature. Randomized control trials demonstrating the clinical benefits of BP lowering on kidney and major cardiovascular events and recording patient-related outcomes are still needed. These trials should define optimal BP targets for kidney transplant recipients. In the absence of kidney transplant-specific evidence, BP targets in kidney transplant recipients should be similar to those in the wider chronic kidney disease population.
Databáze: OpenAIRE
Externí odkaz: